drugset / Trial / NCT07662200
A Simplified Regimen to Prevent Nausea and Vomiting Using Netupitant/Palonosetron in Germ Cell Cancer Patients Receiving Chemotherapy
RandomizedParallel-groupSingle-blindPrevention
Summary
This is a single-site, open-label, randomized pilot feasibility study conducted at The Ottawa Hospital Cancer Centre. A total of 10 participants will be randomized 1:1 to either the experimental or control arm. The purpose of this study is to evaluate recruitment capability, intervention adherence, data completeness, and safety prior to consideration of a potential future multi-centre randomized trial.
Timeline
- Start
- 2026-08
- Primary completion
- 2027-08
- Completion
- 2028-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Aprepitant | Other / unclassified | 80 mg | Oral |
| Subject | Dexamethasone | Small molecule | 8 mg | Oral |
| Subject | Netupitant | Small molecule | 300 mg | Oral |
| Comparator | Ondansetron | Other / unclassified | 8 mg | Oral |
| Subject | Palonosetron | Other / unclassified | 0.5 mg | Oral |
| Background | Olanzapine | Small molecule | 5 mg | Oral |